Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Jones, G Morgan ^a   Twilla, Jennifer D ^a   Hoit, Daniel A ^b   Arthur, Adam S ^b  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b SEMMES MURPHEY NEUROLOGIC AND SPINE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; BARE METAL STENT; BRAIN ANGIOGRAPHY; BRAIN ARTERY ANEURYSM; CAROTID ARTERY ANEURYSM; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM PREVENTION; FEMALE; HUMAN; INCIDENCE; LOADING DRUG DOSE; PRIORITY JOURNAL; RISK REDUCTION; STENT THROMBOSIS; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

EID: 84872161782     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-010482     Document Type: Article

References (12)

1. Nelson PK, Lylyk P, Szikora I, et al. The pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol 2011;32:34-40.
2. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281-5.
3. Chaturvedi S, Yadav JS. The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. Stroke 2006; 37:1572-7.
4. Lutsep HL, Barnwell S, Mawad DC, et al. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388-92.
5. Kang HS, Kwon BJ, Kim JE, et al. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol 2010;31:1206-10.
6. McKevitt FM, Randall MS, Cleveland TJ, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 2005;29:522-7.
7. Bhatt DL, Kapadia SR, Bajzer CT, et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol 2001;13:767-71.
8. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49:2312-17.
9. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
10. Leslie-Mazwi TM, Chandra RV, Oh DC, et al. Novel use of prasugrel for intracranial stent thrombosis. J Neurointerv Surg. Published Online First: 18 February 2011. doi:10.1136/jnis.2010.004382
11. Akbari SH, Reynolds MR, Kadkhodayan Y, et al. Hemorrhagic complications after prasugrel (effient) therapy for vascular neurointerventional procedures. J NeuroIntervent Surg. Published Online First: 7 June 2012. doi: 10.1136/neurintsurg-2012-010406.
12. Erlinge D, Ten Ber J, Foley D, et al. Prasugrel 5 mg in low body weight patients reduces platelet reactivity to a similar extent as prasugrel 10 mg in higher body weight patients: results from the feather trial. J Am Col Cardiol 2012;59 :E341.